Hema-Times: Understanding the Mechanisms of Action of Multiple Myeloma Therapies and their Clinical Implications

Click here to view the full Hema-Times: Understanding the mechanisms of action of multiple myeloma therapies and their clinical implications 2015. 

Click here to view the full Hema-Times: Understanding the mechanisms of action of multiple myeloma therapies and their clinical implications 2015. 

Multiple myeloma (MM) is a plasma cell malignancy based in the bone marrow, in which standard treatments have historically included corticosteroids (e.g. dexamethasone and prednisone) and cytotoxic drugs (e.g. melphalan, vincristine, cyclophosphamide, and doxorubicin). However, the treatment paradigm is shifting away from classical chemotherapy to therapies that more directly target the unique plasma cell biology. This may be either through pathways unique to the plasma cell itself or the tumour microenvironment upon which they are dependent. Significant improvements in overall survival and remission duration in multiple myeloma (MM) are largely due to the advent of novel therapeutic agents, including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs). Newer agents, including those that affect the epigenome, and antibody-based therapies that directly target the plasma cell are also coming into play. As the therapeutic landscape widens, it will be important to study these agents and their mechanisms of action (MoA).

This paper will focus on the MoA of existing and new agents, in order to promote a better understanding of how they work, and what their implications are in the Canadian clinical setting. 

Below is a link to the full publication as well as supplimentary publications: 

Click here for the full publication.

Click here for the full publication.

Click here to read the full CARE Perspectives at CCOLD 2015 Conference Report. 

Click here to read the full CARE Perspectives at CCOLD 2015 Conference Report. 

Click here to read the full Subsequent Entry Biologics Needs Assessment Results. 

Click here to read the full Subsequent Entry Biologics Needs Assessment Results.